Señales en vivo de BGBIO.OL | Maximiza tus Ganancias con Getagraph.com

COMPRAR 1089 min ago

@ NOK0.147

Emitido: 30 abr 2024 @ 08:16

Retorno: -1.09%

Señal anterior: abr 30 - 05:11

Señal anterior: Vender

Retorno: -0.81 %

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 10:25):
Our systems believe the stock currently is undervalued by 1.19% compare to its pairs and should correct upwards.

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
Volumen de hoy	28.91M
Volumen promedio	42.95M
Capitalización de mercado	566.76M
EPS	NOK0 ( 2024-02-15 )
Próxima fecha de ganancias	( NOK-0.0200 ) 2024-05-23
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.260
ATR14	NOK0.00700 (4.83%)

Correlación (AI algo v.1.1b): Undervalued: 1.19% NOK0.147 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.80 (moderate negative)

Corto: 0.00 (neutral)

Signal:(60) Neutral

BerGenBio ASA Correlación

10 Correlaciones Más Positivas
PLT.OL	0.937
ELIMP.OL	0.935
KMCP.OL	0.931
TRVX.OL	0.925
ELABS.OL	0.908
ABG.OL	0.895
AKER.OL	0.893
VOW.OL	0.892
SADG.OL	0.891
EFUEL.OL	0.884

10 Correlaciones Más Negativas
AYFIE.OL	-0.95
ATEA.OL	-0.929
TECH.OL	-0.886
ELK.OL	-0.885
BAKKA.OL	-0.882
BWO.OL	-0.877
PEXIP.OL	-0.871
BOUV.OL	-0.865
GOD.OL	-0.864
SMOP.OL	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BerGenBio ASA Correlación - Moneda/Commodity

0.00
( neutral )

0.35
( neutral )

BerGenBio ASA Finanzas

Annual	2022
Ingresos:	NOK389 000
Beneficio Bruto:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2022
Ingresos:	NOK389 000
Beneficio Bruto:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2021
Ingresos:	NOK774 000
Beneficio Bruto:	NOK0.00 (0.00 %)
EPS:	NOK-3.52

FY	2020
Ingresos:	NOK601 000
Beneficio Bruto:	NOK0.00 (0.00 %)
EPS:	NOK-3.43

Financial Reports:

No articles found.

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.